Are PCSK9 Inhibitors Cost Effective?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Link
http://link.springer.com/article/10.1007/s40273-018-0671-0/fulltext.html
Reference29 articles.
1. World Health Organization. WHO Mortality database. http://www.who.int/healthinfo/mortality_data/en/ . Accessed 23 Dec 2017.
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
3. Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, et al. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35(5):537–47.
4. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.
5. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–82.
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis;International Journal for Equity in Health;2024-06-05
2. Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment;Health Expectations;2024-04
3. Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children;Expert Opinion on Biological Therapy;2024-03-21
4. «Mind the gap». Fundamentos de economía de la salud para una comunicación efectiva entre clínicos y gestores sanitarios;REC: CardioClinics;2023-11
5. A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates;npj Vaccines;2023-09-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3